The global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study by Polaris Market Research. The report “Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia, Others); By Treatment Type (Painkillers and NSAIDs, DMARDs, Biological Therapies, Steroids, Physical Therapies, Surgery); By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Ankylosing Spondylitis (AS), also known as Bechterew disease is the rare type of arthritis causing stiffness and intense pain in the individual’s spine, starting from lower back sacral bones. AS could also spread to the neck region and damage to other adjoining joints. Ankylosis simply means bone fusion and hard connective tissue and spondylitis means inflammation in the spine and lower part of the vertebrae.
However, there is no cure for ankylosing spondylitis, but medication and proper exercise workouts can ease pain in the spine. Ankylosing spondylitis is started from an individual’s sacroiliac joints, where the spinal cord connects with the pelvic girdle. It impacts the connecting regions of tendons and ligaments attached to the bones and can even fuse an individual’s vertebrae.
Ankylosing spondylitis could cause inflammation and stiffness throughout the body, in few cases spine becomes weak, likely to be fractured easily, also interrupts the functioning of the cauda equine, group of nerves responsible for an individual’s bowel movements, reflexes, and sexual desires, around 40 percent of the patients suffering from AS are likely to suffer from eye-related problem uveitis, eye inflammation causing blurred vision, and individuals with AS in rare cases have large aorta.
Still, researchers are not being able to figure out what triggers ankylosing spondylitis, but there is a strong narrative that people with ankylosing spondylitis have a gene that codes protein called human leukocyte antigen B27 (HLA-B27). HLAs are the proteins, which help an individual’s immune system to differentiate between its cells and foreign particles, though, according to the Spondylitis Association of America, only 2 percent of the people in the market having HLA-B27 gene are expected to develop ankylosing spondylitis in the future. Men are more likely to suffer from ankylosing spondylitis than women, it starts during adulthood, 80 percent of the cases usually begin before 30, and more than 95 percent, by the age of 45.
Get Sample PDF clicking the link below: https://www.polarismarketresearch.com/industry-analysis/ankylosing-spondylitis-market/request-for-sample
Rising prevalence of ankylosing spondylitis with faulty lifestyles coupled with patient awareness and new product approvals driving the market forward. According to the recent population estimates the prevalence rate of ankylosing spondylitis in the U.S. is around 0.2-0.5 percent and based on market data from multiple countries the global incidence rate was stood at 0.4-14 per 100,000 individuals.
Ankylosing spondylitis prevalence increase to about 5 percent for the individual who is HLA B27 positive. Companies such as AbbVie, Inc., Pfizer, Inc., Novartis AG, Amgen, Inc., Johnson & Johnson Services, Inc., Eli Lilly and Company, UCB, Inc., and Merck & Co., Inc. are some of the key players operating in the global ankylosing spondylitis market.
